RhumbLine Advisers’s Moderna MRNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $56.7M | Buy |
809,853
+249,494
| +45% | +$12.9M | 0.04% | 349 |
|
|
2026
Q1 | $28.5M | Sell |
560,359
-60,314
| -10% | -$2.81M | 0.02% | 571 |
|
|
2025
Q4 | $18.3M | Sell |
620,673
-41,413
| -6% | -$1.13M | 0.01% | 750 |
|
|
2025
Q3 | $17.1M | Buy |
662,086
+39,229
| +6% | +$1.09M | 0.01% | 815 |
|
|
2025
Q2 | $17.2M | Buy |
622,857
+25,390
| +4% | +$669K | 0.01% | 792 |
|
|
2025
Q1 | $16.9M | Buy |
597,467
+72,464
| +14% | +$2.57M | 0.02% | 771 |
|
|
2024
Q4 | $21.8M | Sell |
525,003
-20,902
| -4% | -$999K | 0.02% | 653 |
|
|
2024
Q3 | $36.5M | Sell |
545,905
-40,087
| -7% | -$3.68M | 0.03% | 440 |
|
|
2024
Q2 | $69.6M | Sell |
585,992
-2,900
| -0.5% | -$367K | 0.07% | 247 |
|
|
2024
Q1 | $62.8M | Buy |
588,892
+4,761
| +0.8% | +$480K | 0.06% | 278 |
|
|
2023
Q4 | $58.1M | Sell |
584,131
-3,281
| -0.6% | -$276K | 0.06% | 278 |
|
|
2023
Q3 | $60.7M | Buy |
587,412
+6,127
| +1% | +$683K | 0.07% | 246 |
|
|
2023
Q2 | $70.6M | Buy |
581,285
+124
| +0% | +$16.5K | 0.08% | 226 |
|
|
2023
Q1 | $89.3M | Sell |
581,161
-7,394
| -1% | -$1.22M | 0.11% | 165 |
|
|
2022
Q4 | $106M | Buy |
588,555
+12,421
| +2% | +$2.03M | 0.14% | 137 |
|
|
2022
Q3 | $68.1M | Buy |
576,134
+5,675
| +1% | +$861K | 0.1% | 182 |
|
|
2022
Q2 | $81.5M | Buy |
570,459
+16,608
| +3% | +$2.37M | 0.12% | 156 |
|
|
2022
Q1 | $95.4M | Buy |
553,851
+25,931
| +5% | +$4.37M | 0.12% | 145 |
|
|
2021
Q4 | $134M | Buy |
527,920
+17,074
| +3% | +$4.99M | 0.16% | 111 |
|
|
2021
Q3 | $197M | Buy |
510,846
+164,555
| +48% | +$60.7M | 0.27% | 72 |
|
|
2021
Q2 | $81.4M | Buy |
346,291
+26,740
| +8% | +$4.78M | 0.11% | 163 |
|
|
2021
Q1 | $41.8M | Buy |
319,551
+1,766
| +0.6% | +$256K | 0.06% | 289 |
|
|
2020
Q4 | $33.2M | Sell |
317,785
-3,795
| -1% | -$384K | 0.05% | 361 |
|
|
2020
Q3 | $22.8M | Buy |
321,580
+3,205
| +1% | +$223K | 0.04% | 432 |
|
|
2020
Q2 | $20.4M | Buy |
318,375
+86,381
| +37% | +$4.73M | 0.03% | 445 |
|
|
2020
Q1 | $6.95M | Buy |
231,994
+40,959
| +21% | +$942K | 0.01% | 836 |
|
|
2019
Q4 | $3.74M | Buy |
191,035
+20,837
| +12% | +$370K | 0.01% | 1439 |
|
|
2019
Q3 | $2.71M | Buy |
170,198
+137,924
| +427% | +$2.04M | 0.01% | 1562 |
|
|
2019
Q2 | $472K | Buy |
32,274
+16,495
| +105% | +$354K | ﹤0.01% | 2385 |
|
|
2019
Q1 | $321K | Buy |
+15,779
| New | +$293K | ﹤0.01% | 2508 |
|
Other funds holding MRNA
TP
RhumbLine Advisers's MRNA Position: Q2 2026 in Review
RhumbLine Advisers increased its Moderna (MRNA) stake by 45% in Q2 2026, buying an estimated $12.9M and bringing the position to 809,853 shares worth $56.7M. The position accounts for 0.04% of the portfolio, ranked #349.
RhumbLine Advisers first reported a position in MRNA in Q1 2019 and has held it in 30 quarters since. The position peaked at $197M in Q3 2021. 775 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.
- RhumbLine Advisers held 809,853 shares of Moderna worth $56.7M as of Q2 2026.
- RhumbLine Advisers bought 249,494 Moderna shares in Q2 2026, an estimated $12.9M.
- Moderna made up 0.04% of RhumbLine Advisers's portfolio in Q2 2026, its #349 holding.
- RhumbLine Advisers first reported a position in Moderna in Q1 2019 and has held it in 30 quarters since.
- RhumbLine Advisers's Moderna position peaked at $197M in Q3 2021.
- 775 funds tracked by Wall St. Rank held Moderna as of Q2 2026.
Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.